Lv2
138 积分 2022-01-13 加入
Statin use and liver-related prognosis among patients with MASLD
1个月前
已完结
Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
1个月前
已完结
Combined TACE with Targeted and Immunotherapy versus TACE Alone Improves DFS in HCC with MVI: A Multicenter Propensity Score Matching Study
1个月前
已完结
Long-Term Outcomes According to Surgical Margin in Mass-Forming Cholangiocarcinoma: The Role of R1vasc
2个月前
已完结
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
2个月前
已完结
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis
2个月前
已完结
Liver decompensation in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab: a real-life study
2个月前
已完结
Dynamic ALBI score and FIB-4 index trends to predict complications after resection of hepatocellular carcinoma: A K-means clustering approach
2个月前
已完结
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study
6个月前
已完结
Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus
6个月前
已完结
皖公网安备34019202002308
